IMPROVING THE EFFECTIVENESS AND SAFETY OF EPIGENETIC EDITING IN BRAIN REGENERATION

REGENERAR aims to develop a non-viral delivery system to reprogram glial cells into neurons for treating CNS injuries, focusing on safety, targeting, and stakeholder collaboration.

Subsidie
€ 2.943.233
2024

Projectdetails

Introduction

The central nervous system has a limited capacity for self-repair. Therefore, technologies to replace lost neurons after an injury, including stroke or neurodegenerative diseases, are of great need.

Project Overview

The project REGENERAR aims to develop a non-viral delivery formulation up to TRL4 for the delivery of an epigenetic reprogramming formulation to reprogram glial cells into neurons.

Testing and Evaluation

The in vitro safety and targeting of the formulation will be tested against glial cells and organotypic cortical slice cultures. Several routes of administration will be tested to enhance the accumulation of the formulation in the brain.

In Vivo Assessment

In addition, the in vivo safety, elimination, targeting, and epigenetic reprogramming will be evaluated.

Toxicological Studies

Toxicological studies will be performed in GLP conditions to evaluate both in vivo systemic and local (brain) effects of the formulation.

Stakeholder Involvement

The development of the non-viral formulation will take into account the contributions of key stakeholders in the area of gene editing, health institutions, patient associations, among others.

Future Planning

A roadmap will be developed for upscaling innovation to higher TRLs upon the end of the action.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 2.943.233
Totale projectbegroting€ 2.943.233

Tijdlijn

Startdatum1-3-2024
Einddatum29-2-2028
Subsidiejaar2024

Partners & Locaties

Projectpartners

  • UNIVERSIDADE DE COIMBRApenvoerder
  • HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH
  • SOCIEDADE PORTUGUESA DE INOVACAO CONSULTADORIA EMPRESARIAL E FOMENTO DA INOVACAO SA
  • FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EV
  • Single Technologies AB
  • HOVIONE FARMACIENCIA SA

Land(en)

PortugalGermanySweden

Vergelijkbare projecten binnen EIC Pathfinder

EIC Pathfinder

New Prime Editing and non-viral delivery strategies for Gene Therapy

This project aims to develop non-viral delivery systems and novel prime editors to enhance gene editing efficiency and safety for treating Sickle Cell Disease and other genetic disorders.

€ 4.406.097
EIC Pathfinder

NOn-VIral gene modified STEM cell therapy

This project aims to develop a high-throughput protocol for producing gene-corrected CAR T cells and blood stem cells using optimized photoporation and CRISPR technology for enhanced clinical application.

€ 3.644.418
EIC Pathfinder

A revolutionary cell programming platform based on the targeted nano-delivery of a transposon gene editing system

The NANO-ENGINE project aims to develop an affordable, scalable, and safe DNA-based in vivo cell programming technology using Targeted Nanoparticles to enhance accessibility of cell therapies for various diseases.

€ 2.988.377
EIC Pathfinder

4-Deep Brain Reconstruction

The 4-DBR consortium aims to develop a transplantable 4D reconstructed brain to regenerate neurological disorders, integrating advanced bioprinting and stimulation technologies for effective therapy.

€ 2.987.775

Vergelijkbare projecten uit andere regelingen

ERC Starting...

Rewiring gene regulatory circuits to enhance central nervous system repair

This project aims to rewire gene expression in mammalian neural stem cells using synthetic enhancers to promote regeneration after CNS injury, enhancing cell replacement and gene therapy strategies.

€ 1.500.000
ERC Consolid...

In Vivo CRISPR-Based Nanoplatform for Gene Editing: A New Disruptive Avenue for Non-Invasive Treatment of Genetic Brain Diseases

This project aims to develop a novel nanoplatform for the safe and efficient delivery of CRISPR gene editing technology to treat genetic brain diseases non-invasively.

€ 2.249.895
ERC Advanced...

A novel and empowered TARGETed gene addition approach at a relevant microglia locus for the treatment of inherited NeuroMetabolic Diseases

Develop a targeted gene addition approach at a microglia locus in HSCs to safely and effectively treat inherited neurometabolic diseases by enhancing timely microglia-like cell engraftment.

€ 2.495.250
ERC Proof of...

Neuroregenerative peptide treatment for multiple sclerosis

REGENERA MS aims to evaluate a novel peptide's feasibility as a cost-effective, neurorestorative treatment for multiple sclerosis, potentially improving patient outcomes and reducing socioeconomic burdens.

€ 150.000
ERC Consolid...

Microglia engineering and replacement to treat brain disease

The ReplaceMi project aims to develop a translatable strategy for replacing dysfunctional microglia with healthy progenitors to treat neurodegenerative diseases through innovative technologies.

€ 2.000.000